Y-Intercept (HK)’s Climb Bio CLYM Stock Holding History

Y-Intercept (HK)’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-127,952	Closed	-$159K	–	2153
2025 Q2	$159K	Buy	+127,952	New	+$159K	﹤0.01%	1491

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Y-Intercept (HK)'s CLYM Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Climb Bio (CLYM) in Q3 2025, closing a stake of 127,952 shares — an estimated $159K sold.

Y-Intercept (HK) first reported a position in CLYM in Q2 2025 and held it in 1 quarter. The position peaked at $159K in Q2 2025. 68 funds tracked by Wall St. Rank hold CLYM as of Q3 2025.

Y-Intercept (HK) reported no remaining Climb Bio position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 127,952 Climb Bio shares in Q3 2025, an estimated $159K.
Y-Intercept (HK) first reported a position in Climb Bio in Q2 2025 and held it in 1 quarter.
Y-Intercept (HK)'s Climb Bio position peaked at $159K in Q2 2025.
68 funds tracked by Wall St. Rank held Climb Bio as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.